Abstract: A Voltage-Controlled Oscillator (VCO) includes a cross-coupled transconductance cell. A transformer comprising a primary coil and at least one secondary coil, wherein the primary coil is connected to the cross-coupled transconductance cell. A primary coil varactor is connected to the cross-coupled transconductance cell in parallel to the primary coil. A variable inductive tuning component connected to the at least one secondary coil. A mode switch connected to the at least one secondary coil and configured to select a frequency mode of operation of the VCO by engaging or disengaging the variable inductive tuning component from operation with the primary coil varactor to generate oscillation at a center frequency of the VCO.

Abstract: A Voltage-Controlled Oscillator (VCO) includes a cross-coupled transconductance cell. A transformer comprising a primary coil and at least one secondary coil, wherein the primary coil is connected to the cross-coupled transconductance cell. A primary coil varactor is connected to the cross-coupled transconductance cell in parallel to the primary coil. A variable inductive tuning component connected to the at least one secondary coil. A mode switch connected to the at least one secondary coil and configured to select a frequency mode of operation of the VCO by engaging or disengaging the variable inductive tuning component from operation with the primary coil varactor to generate oscillation at a center frequency of the VCO.

Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.

Abstract: This invention relates to novel adenoviruses useful in the production of high titers of recombinant adeno-associated virus (rAAV) comprising a foreign DNA inert and methods of making these adenoviruses. The adenovirus comprises the AAV rep gene in which the p5 promoter of rep is replaced by a minimal promoter or by no promoter. The invention also provides methods of producing high levels of rAAV as a substantially homogeneous preparation and compositions of rAAV.

Abstract: A wide linear range peak detector including first and second peak detectors and a compensation circuit. The first peak detector receives an input signal and has an output providing a first peak signal approximation which approximates a peak level of the input signal. The first peak signal approximation includes a non-linear portion which is a function of the peak level of the input signal. The second peak detector also receives the input signal and has an output providing a second peak signal approximation. The compensation circuit uses the second peak signal approximation to provide a compensation signal which compensates the non-linear portion of the first peak signal approximation. In particular, the second peak signal is used to generate the compensation signal to approximate and cancel the non-linear portion.

Abstract: This invention relates to novel adenoviruses useful in the production of high titers of recombinant adeno-associated virus (rAAV) comprising a foreign DNA insert and methods of making these adenoviruses. The adenovirus comprises the AAV rep gene in which the p5 promoter is replaced by a minimal promoter or by no promoter. The invention also provides methods of producing high levels of rAAV as a substantially homogenous preparation and composition of rAAV.

Abstract: The present invention relates generally to immunization methods using recombinant viral vectors. In particular, the invention relates to methods and compositions for immunizing a subject with a nucleic acid molecule encoding an antigen of interest, wherein the nucleic acid molecule is delivered to the subject via a recombinant AAV virion.

Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved.

Abstract: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is disclosed, The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of a delivered nucleotide sequence encoding erythropoietin, and for in vivo secretion thereof from transduced muscle cells such that systemic delivery is achieved.

Abstract: The present invention provides methods and compositions for producing high titer preparations of recombinant AAV (“rAAV”) virions. The compositions of the present invention include AAV helper function systems and host cells. The present invention also includes methods of using AAV helper function vectors that effect the production of only small amounts of the long forms of Rep protein, and rAAV virions produced by such methods.

Abstract: The present invention provides methods and compositions for producing high titer preparations of recombinant AAV (“rAAV”) virions. The compositions of the present invention include AAV helper function systems and host cells. The present invention also includes methods of using AAV helper function vectors that effect the production of only small amounts of the long forms of Rep protein, and rAAV virions produced by such methods.

Abstract: The present invention provides methods and compositions for producing high titer preparations of recombinant AAV (“rAAV”) virions. The compositions of the present invention include AAV helper function systems and host cells. The present invention also includes methods of using AAV helper function vectors that effect the production of only small amounts of the long forms of Rep protein, and rAAV virions produced by such methods.

Abstract: The present invention provides methods and compositions for producing high titer preparations of recombinant AAV (“rAAV”) virions. The compositions of the present invention include AAV helper function systems and host cells. The present invention also includes methods of using AAV helper function vectors that effect the production of only small amounts of the long forms of Rep protein, and rAAV virions produced by such methods.

Abstract: The present invention provides methods and compositions for producing high titer preparations of recombinant AAV ("rAAV") virions. The compositions of the present invention include AAV helper function systems and host cells. The present invention also includes methods of using AAV helper function vectors that effect the production of only small amounts of the long forms of Rep protein, and rAAV virions produced by such methods.

Abstract: A novel nucleotide sequence integration and targeting system is described. The system employs adeno-associated virus (AAV) derived vectors which include a selected nucleotide sequence bounded by AAV inverted terminal repeats (ITRs). An AAV rep coding region is also provided, enabling the targeted integration of the selected nucleotide sequence into the genome of a suitable target cell. The nucleotide sequence integration system of the present invention can deliver and integrate large segments of DNA into the genome of target cells. Further, the subject integration system provides the advantage of site-specific integration of the selected nucleotide sequences in a target cell genome, thereby avoiding insertional mutagenesis events experienced with prior systems.

Abstract: A programmable frequency synthesizer is disclosed having most components implemented on a single large scale integration (LSI) chip, which facilitates rapid frequency acquisition. Provision is made by the present invention to configure the frequency synthesizer for use in either a receiver or a transmitter. In the transmitter mode, modulation cancelling allows modulation down to approximate DC. A serial programming protocol is provided to program the frequency synthesizer.